TY - JOUR
T1 - Multi-OMICs and genome editing perspectives on liver cancer signaling networks
AU - Lin, Shengda
AU - Yin, Yi A.
AU - Jiang, Xiaoqian
AU - Sahni, Nidhi
AU - Yi, Song
N1 - Publisher Copyright:
© 2016 Shengda Lin et al.
PY - 2016
Y1 - 2016
N2 - The advent of the human genome sequence and the resulting 20,000 genes provide a crucial framework for a transition from traditional biology to an integrative "OMICs" arena (Lander et al., 2001; Venter et al., 2001; Kitano, 2002). This brings in a revolution for cancer research, which now enters a big data era. In the past decade, with the facilitation by next-generation sequencing, there have been a huge number of large-scale sequencing efforts, such as The Cancer Genome Atlas (TCGA), the HapMap, and the 1000 genomes project. As a result, a deluge of genomic information becomes available from patients stricken by a variety of cancer types. The list of cancer-Associated genes is ever expanding. New discoveries are made on how frequent and highly penetrant mutations, such as those in the telomerase reverse transcriptase (TERT) and TP53, function in cancer initiation, progression, and metastasis. Most genes with relatively frequent but weakly penetrant cancer mutations still remain to be characterized. In addition, genes that harbor rare but highly penetrant cancer-Associated mutations continue to emerge. Here, we review recent advances related to cancer genomics, proteomics, and systems biology and suggest new perspectives in targeted therapy and precision medicine.
AB - The advent of the human genome sequence and the resulting 20,000 genes provide a crucial framework for a transition from traditional biology to an integrative "OMICs" arena (Lander et al., 2001; Venter et al., 2001; Kitano, 2002). This brings in a revolution for cancer research, which now enters a big data era. In the past decade, with the facilitation by next-generation sequencing, there have been a huge number of large-scale sequencing efforts, such as The Cancer Genome Atlas (TCGA), the HapMap, and the 1000 genomes project. As a result, a deluge of genomic information becomes available from patients stricken by a variety of cancer types. The list of cancer-Associated genes is ever expanding. New discoveries are made on how frequent and highly penetrant mutations, such as those in the telomerase reverse transcriptase (TERT) and TP53, function in cancer initiation, progression, and metastasis. Most genes with relatively frequent but weakly penetrant cancer mutations still remain to be characterized. In addition, genes that harbor rare but highly penetrant cancer-Associated mutations continue to emerge. Here, we review recent advances related to cancer genomics, proteomics, and systems biology and suggest new perspectives in targeted therapy and precision medicine.
UR - http://www.scopus.com/inward/record.url?scp=84976604739&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976604739&partnerID=8YFLogxK
U2 - 10.1155/2016/6186281
DO - 10.1155/2016/6186281
M3 - Review article
C2 - 27403431
AN - SCOPUS:84976604739
SN - 2314-6133
VL - 2016
JO - BioMed research international
JF - BioMed research international
M1 - 6186281
ER -